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Clinical Practice Points: 
* What is already known about this subject?  
Few series with small samples have been published. This study remains the 
biggest in the literature on the subject in collaboration with several centres through 
Europe and USA. 
* What are the new findings? 
Complication rates and positive surgical margins are similar to open surgery. 
* How might it impact on clinical practice in the foreseeable future? 
  Open surgery is still the gold standard for tumors >10 cm. This study 
demonstrates the safety of laparoscopy in such indication, with comparable rates of 
complications and positive margins.  
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Abstract
Objective: Evaluate the feasibility of laparoscopic nephrectomy (LN) for big tumors. 
Material & Methods: Data from 116 patients were retrospectively collected from 16 
tertiary centres. Clinical and operative parameters, tumor characteristics, per and 
post operative parameters and renal function before and after surgery were analyzed.  
Results: Mean age and BMI were 61 y.o and 27.8 kg/m², respectively. Males 
represented 63.8% and 54.4% presented symptoms at diagnosis. Median tumor size 
was 11 cm and 75% of the cases were performed by expert surgeons. Median 
operative time and blood loss were 180 min and 200ml respectively. Conversion to 
open surgery was necessary in 20.7%. Intra operative complications related to 
massive haemorrhage occurred in 16.4%, resulting in open conversion in 62.5%. 
Major postoperative complications occurred in only 10 patients (8.6%). In univariate 
analysis, intra operative complications, age and blood loss were predictive factors of 
conversion to open surgery. Positive surgical margins occurred in 6 patients (5.2%). 
None of them presented a local recurrence. Predictive factors of recurrence or 
progression were lymph node invasion, metastases and Furhman grade. 
Conclusion:  
LN for tumors>10 cm can be performed safely. Complication rate and positive 
surgical margins are similar to open surgery. In experienced hands, the benefit of a 
mini invasive surgery remains evident. 
Microabstract 
116 patients who had a laparoscopic nephrectomy (LN) for big tumors were included. 
Conversion to open surgery was necessary in 20.7%.Haemorrhage occurred in 
16.4%, resulting in open conversion in 62.5%. Intra operative complications, age and 
blood loss were predictive factors of conversion to open surgery. LN for tumors>10 
cm can be performed safely with comparable results to open surgery. 
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Introduction 
The management of renal tumors has greatly evolved over the last decades. 
Renal lesions are discovered at an earlier stage and these small renal masses are 
mostly treated by partial nephrectomy1.  
However, urologists are still confronted to large tumors that require a radical 
nephrectomy. Because of decreased morbidity, laparoscopic radical nephrectomy 
(LRN) has become the standard treatment of T1 and T2a tumors that are not 
amenable to partial nephrectomy. Many studies have confirmed that oncological 
outcomes were similar to that of open surgery2. 
With growing experience of surgeons worldwide, the laparoscopic approach 
has progressively been extended to voluminous kidneys3 (such as the ones seen in 
polycystic kidney disease), and despite technical difficulties, some teams routinely 
consider LRN for big renal tumors4-7. However, there have been concerns regarding 
the safety of laparoscopy for the excision of bulky renal tumors and there is limited 
published data on oncological outcomes of LN for big renal tumors. 
Our objective was to evaluate the outcomes of LRN for large renal tumors 
(defined as > 10cm) in a contemporary multicentric series. 
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Material & Methods 
Study design  
This was a retrospective study that included 116 patients who underwent pure 
LRN for a large tumor (defined as a diameter > 10 cm on pathological exam). 
Patients included underwent surgery between 2004 and 2013. After institutional 
approval, data were extracted from kidney cancer databases from 16 tertiary 
urological centres with common practice of LRN in France, the Netherlands, Turkey, 
Czech Republic and the United States. There was no robotic or hand-assist 
procedures. Patients with caval thrombus were excluded. Lymphadenectomy was not 
systematically performed and was left at the surgeon’s discretion. 
Some patients had metastatic disease and received adjuvant interferon, 
interleukin 2-based immunotherapy or more recently antiangiogenics treatments. 
Post-operative follow-up was specific to each institution. 
Data collection 
Clinical parameters included age, gender, body mass index (BMI), Charlson 
comorbidity index, history of hypertension or diabetes mellitus, Eastern Cooperative 
Oncology Group (ECOG) performance status (PS), ASA score, symptom  score (S 
classification), need for post operative haemodialysis. Data regarding kidney function 
included pre and post operative glomerular filtration rate (GFR) estimated by the 
abbreviated Modification of Diet and Renal Disease (MDRD) equation8.  
Pathological features included tumor size, histological subtype, TNM stage 
(2009 TNM classification 9), and Fuhrman grade. Histological subtypes were stratified 
according to the World Health Organization classification 10. 
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The following peri-operative parameters were analyzed: type of surgery 
(robotic or laparoscopic), operative time, blood loss, transfusion rate, location of the 
tumor (upper, mid or lower pole), intra and post-operative complications (graded 
according to Clavien’s classification), length of hospital stay, and surgeon’s 
experience (a surgeon was considered experienced if he had performed more than 
20 LRN as defined in several studies5-7). 
 Intra operative complications included those that required immediate 
treatment, such as vascular or organ injury and were not considered in the post 
operative Clavien’s classification. Conversion to open surgery was not considered as 
a complication.  
At last follow up, patients were considered as living (with or without disease) or 
deceased (from renal cancer or from any other cause). 
Statistical analyses  
Continuous variables are presented as mean ± standard deviations or median 
± inter-quartile range (IQR). Categorical variables are presented as counts and 
percentages. Association between binary outcomes (i.e., surgical conversion, post-
operative complications and cancer recurrence/progression) and selected covariates 
was assessed using either Fisher exact test (for binary covariates) or ridit score (for 
ordinal covariates) or Wilcoxon test (for continuous covariates). Odds ratio and 95% 
Wald confidence limits were used as measure of association. Covariates statistically 
associated in univariate analyses were considered for multivariate logistic regression 
modeling. All analyses used procedures from SAS 9.3 (SAS Institute, Cary, N.C., 
USA). 
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Results 
Mean age was 61 years old and most of the patients were males (64%). Mean 
BMI was 27.8 kg/m². The majority of the population had few co morbidities (81.6% of 
ASA score 1-2 and median Charlson comorbidity index score of 2). 53.4% of the 
patients had local or general symptoms, and 37.2% had an altered performance 
status (table 1). 
Operative parameters 
Most of the procedures (75%) were performed by expert surgeons. Median tumor 
size was 11 cm. Median operative time was 180 min, and median blood loss was 200 
ml. Intra operative complications occurred in 16.3% of the cases and were all related 
to haemorrhage. A conversion to open surgery was necessary in 20.7% of the cases, 
mostly because of intra operative bleeding or a difficult dissection related to tumor 
volume.  In case of intra operative complication, a conversion to open surgery was 
needed in 62.5% of the cases. One third of the patients had post operative 
complications, but the majority was low grade (10 patients had a high grade 
complication) (Table 1). 6% of the patients had to be reoperated. Reoperation was 
mainly related to post-operative hemorrhage. One patient presented bleeding from 
the adrenal, another had to have a splenectomy, two had bleeding from the 
abdominal wall (epigastric vessel injury), and one had a wound abscess that needed 
surgical drainage. Finally, only one patient had an abdominal repair at distance due 
to evisceration There was no death secondary to surgery. 
Pathological examination and clinical evolution 
Pathological analysis showed that most of the tumors were of high stage and grade, 
and clear cell carcinoma was the most frequent histological subtype (table 1). Seven 
patients had a positive margin and one had metastatic progression at 6 months.  
Local recurrence was observed in ten patients (8.7%). Fifteen patients (12.9%) had 
metastatic progression and 12.1% died from their cancer.  
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Predictive factors of surgical conversion and complications 
In univariate analysis, age, blood loss and intra operative complications were 
associated with a significant risk of conversion. Less experienced surgeons had more 
open conversions although not significant (p= 0.059) (table 2). In multivariate 
analysis, the only predictive factor of conversion was the occurrence of an intra 
operative complication (OR 26.3; p= 0.001).  
Factors associated with post-operative complications were the occurrence of an intra 
operative complication, operative time and surgeon’s expertise (table 3). In 
multivariate analysis surgeon’s experience tended to be associated with the 
occurrence of a post-operative complication (p= 0.06). 
Predictive factors of recurrence/progression and progression free-survival 
Since there was a limited number of local recurrence and/or metastatic progression, 
we considered those two events similarly as cancer recurrence. Variables associated 
with cancer recurrence were: lymph node invasion, presence of metastases at 
diagnosis, and Fuhrman grade. Operative parameters such as blood loss, operative 
time and conversion to open surgery or complications had no impact on progression 
free survival (table 4). Similarly a positive surgical margin did not increase the risk of 
cancer progression (p= 0.97). 
Progression-free survival analysis was conducted in 112 patients with malignant 
tumors (two patients had benign tumors on final histology, and in two others, 
pathology was missing). Twenty one patients experienced a pre-specified qualifying 
event: 6 recurrences, 12 progression and 3 cancer deaths. Median time to event 
occurrence was 6 months (min, max [IQR]: 2, 29 [4-12]). Kaplan-Meier survival 
estimates for progression-free survival are displayed in figure 1. 
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Discussion 
  
LRN has become the standard of care for the treatment of localized kidney 
tumors not amenable to partial nephrectomy. It can be considered to treat larger 
tumors, but little is known about the outcomes of LRN for big tumors.  
We report the results of a large multicentric series that shows that LRN for big 
renal tumors is feasible and safe: there was no death related to surgery and most of 
the complications that occurred were of low grade. However, it is technically 
challenging with an open conversion rate of 20%. Removing such large tumours 
requires an extended laparoscopic experience: working space is limited because of 
the volume of the kidney which makes the pedicle dissection more difficult. 
Significant neo-vascularisation is frequently encountered around the kidney which 
increases the risk of bleeding and conversion. However our median blood loss was 
200 ml which is comparable to open series11.  
 There is limited data in the literature concerning LRN for very large tumors. 
Several authors reported their experience of LRN for tumors >7 cm but median tumor 
size in those series was always < 10 cm with a limited number of patients with bulky 
tumors4, 5, 12, 13. 
When compared to open series12 13, we had similar complications rate and a 
shorter length of stay. Therefore, it seems that the benefits of laparoscopy observed 
for smaller renal tumors are also present for large renal masses4, 12, 13. In a 
multicentric study comparing LRN with open surgery for tumors > 7cm, Jeon reported 
significantly less blood loss in the laparoscopic group (439 vs. 604 ml, p= 0.006), and 
comparable intra operative complication rates (10.2% vs. 14.4%, p= 0.34)12. In 
another study comparing LRN for tumors between 7 and 10 cm and for tumors > 10 
cm, there was no difference in terms of peri-operative morbidity 5. These results and 
ours show that provided that a surgeon has the expertise, laparoscopy can be 
considered for large tumors without any fear of increasing the risk of post-operative 
complications.  
 An important finding of our study is that LRN oncological outcomes are similar 
to that of open surgery. There have been concerns regarding the safety of 
laparoscopy, particularly for the removal of bulky tumors, with descriptions of port site 
recurrences or hypothetical fears of peritoneal dissemination related to the 
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pneumoperitoneum. However, with growing laparoscopic experience worldwide, 
many studies have put forward the safety of laparoscopy5-7, 12, 13 even in the case of 
cytoreductive surgery14. Our study supports those findings in the subset of large renal 
tumors. Even in patients with positive margins, where one can hypothesize that there 
were tumoral effraction during surgery, we did not observe any increased recurrence 
rate. Only 8.7% of our patients had a local recurrence which is comparable to the 8.3-
9.3% rates reported in open series for pT3 tumors15, 16. Such findings had already 
been reported for tumours > 7 cm 12. Progression mostly occurred in patients with 
high stage and high grade disease.  
Interestingly, most of the procedures were performed after 2008 which reflects 
the changing evolution of surgical practices. We don’t have any data regarding the 
age of the surgeons who did the surgery but with the turnover of urologic surgeons’ 
who were trained in the era of laparoscopy, it is highly probable that laparoscopic 
procedures will become more and more frequent even for challenging cases.  
 This study has several limits. First, this is a retrospective and multicentric 
study with inherent biases related to data recollection. The choice of laparoscopy was 
specific to each institution and we don’t have any insight regarding selection criteria. 
Second, we don’t have any open control group for direct outcome comparison. Finally 
there is some heterogeneity regarding the contribution of the centers involved in the 
study with 44% of the patients brought by three institutions. So there might be some 
variability regarding surgeon’s expertise. Finally, follow-up is too short to optimally 
appreciate oncological safety.   
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Conclusion 
Large renal tumours can safely be removed by laparoscopy, provided 
adequate surgical expertise. Conversion rate is high but complication rates are 
similar to that of open surgery. Additional follow-up is needed to ensure oncological 
outcomes are favourable.   
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Variables Results 
Mean age (years), mean ± SD 61 ± 13 
Sex ratio: men, n (%) 74 (63.8) 
HTA, n (%) 63 (54.3) 
Diabetis mellitus, n (%) 18 (16.1) 
ASA score, n (%)       1 
2 
3 
25 (21.9) 
68 (59.6) 
21 (18.4) 
Charlson comorbidity index score (n= 95), median 
[range] 2 [0-11] 
Symptom, n (%)         asymptomatic 
local symptoms  
general symptoms  
54 (46.6) 
45 (38.8) 
17 (14.6) 
BMI (kg/m²), mean ± SD 27.8 ± 5.8 
ECOG = 0, n (%) 64 (62.7) 
Expert surgeon (>20 LN), n (%) 75% 
Operative time (min), median [IQR] 180 [130 – 211] 
Blood loss (ml), median [IQR] 200 [100-500] 
Tumor size (cm), median [IQR] 11 [10.2-17] 
Hospital  stay (day), median [IQR] 6 [4-7,5] 
Follow-up (month), median [IQR] 15 [7- 34] 
Conversion to open surgery: n (%) 
- bleeding 
- tumor volume/adhesions 
24 (20.7) 
13 (54.2) 
11 (45.8) 
Intra operative complications, n (%) 19 (16.4) 
Medical complications, n (%) 16 (13.8) 
Surgical complications, n (%) 16 (13.8) 
Blood transfusion, n (%) 15 (12.9) 
Major complications: Clavien  3, n (%) 10 (8.6) 
Postoperative renal function: n (%) 
Down staged 
Stable 
Up staged
47 (48.4) 
36 (37.1) 
14 (14.4) 
pT stage:                     pT2b 
                                    pT3a 
                                    pT4 
44 (39.6) 
65 (58.6) 
2 (1.8) 
N0, n (%) 102 (91.9) 
M1, n (%) 17 (15.3) 
Fuhrman grade 3-4 (n=103)  73 (70.9) 
Histologic subtypes:   Clear cell 
                                   Papillary 
                                   Chromophobe 
                                   Undetermined 
                                   Benign tumors 
77 (66.4) 
21 (18.1) 
10 (8.6) 
6 (5.2) 
2 (1.7) 
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Positive margins, n (%) 6 (5.2) 
Local recurrence, n (%) 10 (8.7) 
Progression, n (%) 15 (12.9) 
Death from cancer, n (%) 14 (12.1) 
Death, n (%) 17 (14.6) 
Table 1: Epidemiological, operative characteristics, pathological and 
oncological parameters of the patients who had a LN for tumors >10 cm 
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Univariate Variables OR 95% CL p 
 Sex 1.34 0.53 - 3.35 0.63 
 Age (per 10 years) 1.51 1.03 -  2.22 0.03 
 ASA score                              2 vs. 1 
3 vs. 1 
4.14 
2.71 
0.89 - 19.3 
0.44 - 16.5 0.29 
 Charlson comorbidity index  2 vs. 0-1 
 3 vs. 0-1 
0.48 
0.98 
0.10 - 2.64 
0.23 - 5.08  0.31 
 ECOG                                    1 vs. 0 
2 vs. 0 
0.69 
0.60 
0.24 - 1.98 
0.06 - 5.53 0.85 
 BMI (per 5 kg/m²) 0.97 0.64 - 1.42 0.98 
 Surgical expertise 0.76 0.28 - 2.08 0.059 
 Intra operative complications 36.6 10.0 - 134 < 
0.0001 
 Blood loss (per 200 mL) 1.76 1.35 - 2.45 < 
0.0001 
Multivariate Variables OR 95% CL p 
 Age (per 10 years) 1.33 0.75 - 2.36 0.33 
 Intra operative complications 26.3 3.62 - 191 0.001 
 Blood loss (per 200 mL) 1.13 0.81 - 1.58 0.48 
Table 2: Predictive factors of surgical conversion to open surgery in uni and 
multivariate analysis. 
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Univariate Variables OR 95% CL Wald chi-
square p-
value 
 Age (per 10 years) 1.30 0.93 - 1.86 0.14 
 ASA score                              2 vs. 1 
3 vs. 1 
1.23
2.00 
0.40 - 3.80
0.53 - 7.60
0.55 
 Diabetes mellitus 1.64 0.55 - 4.87 0.38 
 Charlson comorbidity index  2 vs. 0-1 
(n = 95)                                   3 vs. 
0-1 
1.47
1.50 
0.30 - 10.7
0.32 - 10.8  
0.89 
 BMI (per 5 kg/m²) 1.24 0.85 - 1.80 0.26 
 Operative time (n=108) (per 60 min) 1.57 1.05 - 2.39 0.03 
 Blood loss (n=89) (per 200 mL) 1.14 0.98 - 1.35 0.11 
 Intra operative complications 2.80 0.99 - 7.88 0.05 
 Non expert surgeon 2.52 1.00 - 6.30 0.049 
Multivariate Variables OR 95% CL Wald chi-
square p-
value 
 Intra operative complications 2.70 0.94 - 7.75 0.06 
 Non expert surgeon 2.44 0.96 - 6.21 0.06 
Table 3: Predictive factors of any grade of postoperative complications in uni 
and multivariate analysis 
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Univariate Variables HR 95% CL p 
 T 1.67  0.74 - 3.78 0.2165 
 N 5.63 2.05 - 15.5 0.0008 
 M 5.85  2.39 - 14.3 0.0001 
 Fuhrman grade 2.48  1.33 - 4.60 0.0040 
 Histological subtype    
Papillary vs. clear cell 0.82  0.27 - 2.46 0.7259 
Chromophobe vs. clear cell 0.50 0.07 - 3.78 0.5015 
 Positive margins 0.97  0.13 - 7.24 0.9739 
ECOG                               1 
vs. 0
2.24 0.88 - 5.69 0.0886 
2 vs. 0 1.32  0.17 - 10.4 0.7931 
 Conversion to open surgery 1.46  0.56 - 3.76 0.4354 
 Intra operative complication  1.11 0.37 - 3.29 0.8560 
 Post operative complication 1.88 0.76 - 4.68 0.1734 
 Tumor size 1.06  0.79 - 1.42 0.6746 
 Blood loss (per 200 mL) 0.91  0.69 - 1.19 0.4893 
 Operative time (per hour) 1.08  0.71 - 1.64 0.7227 
Multivariate Variables HR 95% CL p 
 N 2.69  0.95 - 7.62 0.0614 
 M 4.08 1.63 - 10.2 0.0026 
 Fuhrman grade 2.42  1.21 - 4.84 0.0126 
Table 4: Predictive factors of local recurrence and/or progression in uni and 
multivariate survival analysis 
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Figure 1: Kaplan-Meier survival estimate for progression-free survival (months). 
